Anticorps Polyclonal de lapin anti-LRFN2

LRFN2 Polyclonal Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 27576-1-PBS

Synonymes

FIGLER2, KIAA1246, RP11 535K1.2, SALM1



Informations sur le produit

27576-1-PBS cible LRFN2 dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène LRFN2 Protéine recombinante Ag24558
Nom complet leucine rich repeat and fibronectin type III domain containing 2
Masse moléculaire calculée 789 aa, 85 kDa
Poids moléculaire observé85-100 kDa
Numéro d’acquisition GenBankBC142616
Symbole du gène LRFN2
Identification du gène (NCBI) 57497
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

LRFN2, also known as SALM1. It is mainly located in cell membrane and cytoplasm, and it is expressed at the synaptic contact at the base of cone cells, especially at the base of presynaptic endings, which is closely related to the dendrites of OFF bipolar cells (PMID: 40251167). In mammals, LRFN2 is mainly expressed in cone cells, but not in rod cells, and its expression in other retinal neurons is limited. In addition, the expression level in embryonic nerve cells is relatively low, mainly in more mature cells. LRFN2 plays a key role in synaptic transmission between cone cells and OFF bipolar cells. It can maintain the physical connection between cone cells and OFF bipolar cells, and gather glutamate receptors at the postsynaptic membrane to ensure strong dendritic transmission in OFF pathway, thus participating in the transmission of visual signals, which is very important for the coding of visual contrast and the defense behavior driven by looming. In bladder cancer, the increased expression of LRFN2 will inhibit the infiltration and functional transformation of CD8+ T cells, thus weakening the anti-tumor immune response, leading to bladder cancer resistance to immune checkpoint inhibitors, and its high expression is related to the poor prognosis of bladder cancer patients (PMID:37802603).

{{ptg:RelatedPrimaryAntibodies}}